Maynard Um
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Atossa Genetics (ATOS)
-
-
-
-
-
-
-
Atossa streamlines breast cancer trial to cut costs and focus on 2026 NDA plans
-
-
-
-
-
-
-
Atossa Genetics (ATOS) PT Raised to $7.50 at Ascendiant Capital
-
-
-
-
-
-
-
Atossa Therapeutics (ATOS) Issues New U.S. Patent
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Atossa Genetics (ATOS)
-
-
-
-
-
-
-
Atossa Genetics (ATOS) Tops Q2 EPS by 1c
-
-
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

